Insider

ELI Lilly & Co

LLY Health Care · 1 analysis

ELI Lilly reported $24.4B in revenue (+38.6% YoY), compared with a +7.2% median across covered Health Care peers. 1 insider sale recorded.

Mentioned in recent filings: Russia Tariffs

What changed

What changed

Eli Lilly continues clinical research in September 2026

Between September 14 and September 29, 2026, Eli Lilly conducted several clinical trials, including studies of new compounds and the completion of a Phase 4 trial for diabetes treatment. These activities aim to assess the therapeutic potential of experimental agents and new indications for existing drugs.

· ELI Lilly & Co

Company history

October 2026

ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-10.

  • 2026-10-08: Participants receive eloralintide subcutaneously as the experimental intervention. Source
  • 2026-10-08: Participants receive single doses of LY4268989 in six treatment arms, with high‑fat and fasted states. Source
  • 2026-10-08: The study enrolls 123 healthy participants and includes four inpatient stays at the clinical research unit. Source
  • 2026-10-08: The study has four parts: single-ascending dose, multiple-ascending dose, single dose in three periods, and midazolam co‑administration. Source
  • 2026-10-08: The trial is recruiting participants with overweight or prediabetic conditions to receive the investigational drug Orforglipron orally. Source
  • 2026-10-08: Participants will receive LY4329090 administered subcutaneously (SC). Source
  • 2026-10-08: The study includes two parts: Part A lasting about 10 weeks with 5 nights stay and 5 outpatient visits, Part B lasting about 21 weeks with 4 stays totaling 11 nights and 14 outpatient visits. Source
  • 2026-10-08: The study is a randomized, parallel, double‑masked, basic science interventional study with estimated enrollment of 184 participants. Source
  • 2026-10-08: The study will enroll 161 participants and is a Phase 2 randomized, open-label, parallel-design intervention study. Source
  • 2026-10-08: The study will evaluate vepugratinib in adults with low‑grade, intermediate‑risk non‑muscle invasive bladder cancer or low‑grade upper tract urothelial carcinoma. Source
  • 2026-10-09: The primary purpose of the study is basic science evaluating the safety and tolerability of LY5625575. Source
  • 2026-10-09: The study will include healthy participants and participants with elevated high-sensitivity C-reactive protein. Source

September 2026

ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-09.

  • 2026-09-23: The intervention includes abemaciclib in three formulations: Tablet Test Formulation 1, Oral Granules Test Formulation 2, and Reference Tablet Formulation 1. Source
  • 2026-09-23: The trial will last about 8 weeks, including screening and follow-up. Source
  • 2026-09-24: The trial is a phase 2, nonrandomized, sequential, open-label, single‑arm study of mosunetuzumab plus pirtobrutinib in relapsed or refractory Waldenstrom’s Macroglobulinemia. Source
  • 2026-09-24: Patients must be ≥18 years with measurable Waldenstrom’s Macroglobulinemia and have relapsed or refractory disease after at least one prior line of therapy. Source
  • 2026-09-24: The total number of cycles administered is 18 for patients with a complete, very good partial or minor response in dosing strategy 1 and 19 in dosing strategy 2. Source
  • 2026-09-28: The trial is a prospective, single-arm, nonrandomized, open-label, phase I/II study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) in patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases. Source
  • 2026-09-28: Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. Source
  • 2026-09-28: The trial intervention included subcutaneous injections of insulin lispro-aabc (also known as LY900014 or Lyumjev) combined with insulin glargine (Basaglar). Source
  • 2026-09-28: The company's product, baricitinib (Olumiant), was evaluated in a Phase 2 study for the treatment of central centrifugal cicatricial alopecia in adults of African descent. Source
  • 2026-09-28: In a Phase 2 trial of baricitinib for central centrifugal cicatricial alopecia, 27 participants received at least one dose and 17 completed the 52-week treatment period. Source
  • 2026-09-29: Eli Lilly and Company is conducting a Phase 1 study to evaluate the tolerability and side effects of the drug LY4057996 in healthy participants and those with Type 1 or Type 2 Diabetes. Source
  • 2026-09-29: The study arms include experimental groups testing LY4057996 administered subcutaneously or intravenously, alone or in combination with other agents such as Lispro and basal insulin, against placebo and active comparators. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 29, 2026. SEC

LatestEarlierChange
Revenue quarter$24.4B$17.6B+38.6%
Net income quarter$6.5B$5.6B+15.5%
Diluted EPS quarter$7.22$6.21+16.3%
Dividends per share year to date$3.46$3.00+15.3%
Operating cash flow year to date$27.4B$13.6B+101.8%
Cash and cash equivalents balance$4.9B$7.3B-32.8%
Long-term debt balance$47B$40.9B+15.0%

Next results expected around January 28, 2027 (estimate: the quarter ending about December 30, 2026 plus the 29 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
ELI Lilly & Co LLY$24.4B+38.6%—
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 2, 2026Anat HakimSale 10b5-1 plan5,000$1,402.52$7,012,600SEC
October 30, 2026Lilly Endowment, Inc.Planned sale295,000—$405,241,500SEC
October 15, 2026Lilly Endowment, Inc.Planned sale305,000—$368,665,700SEC
October 7, 2026Lilly Endowment, Inc.Planned sale300,000—$347,247,000SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock67,936,153$78,607,563,355+0.6%Q3 2026
State Street36,848,565$42,636,737,590+1.7%Q3 2026
Fidelity (FMR)29,959,147$34,665,130,320+5.3%Q3 2026
Geode Capital Management20,556,572$23,722,722,425+1.2%Q3 2026
Capital Research Global Investors16,998,595$19,670,092,948-18.6%Q3 2026
Norges Bank (Norway's sovereign fund)11,471,413$13,759,156,895—Q2 2026
Wellington Management11,048,493$12,783,990,282+0.5%Q3 2026
Citadel Advisors681,483$788,530,350-27.9%Q3 2026
Two Sigma Investments339,220$392,504,678+317.6%Q3 2026
D. E. Shaw & Co.316,379$366,075,814-36.3%Q3 2026
Millennium Management199,938$231,344,261+9.4%Q3 2026
ARK Investment Management (Cathie Wood)107,838$124,776,742+39.6%Q3 2026
Bridgewater Associates94,722$109,600,932+8.8%Q3 2026
Soros Fund Management22,199$25,686,0190.0%Q3 2026
T. Rowe Price13,383,370$15,485,631-3.8%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.